GSK-4381562 represents a highly specialized fully human monoclonal antibody specifically engineered to target the human PVR-related immunoglobulin domain-containing protein with exceptional binding affinity and selectivity, effectively facilitating the measurable blockade of the inhibitory interaction between PVRIG and its primary ligand PVRL2 across various preclinical experimental models to evaluate the restoration of anti-tumor cytotoxic responses during strictly monitored laboratory observation periods.